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Delirium is not associated with
anticholinergic burden or polypharmacy
in older patients on admission to an
acute hospital: an observational case
control study
Hannah C. Moorey1,2, Sebastian Zaidman2 and Thomas A. Jackson1,3*
Abstract
Background: Older people are commonly prescribed multiple medications, including medications with
anticholinergic effects. Polypharmacy and anticholinergic medications may be risk factors for the development of
delirium.
Methods: Patients from a medical admission unit who were over 70, with DSM-IV diagnosed delirium and patients
without delirium, were investigated. Number of drugs prescribed on admission and anticholinergic burden using
two scales (the Anticholinergic Cognitive Burden Scale [ACB] and the Anticholinergic Drug Scale [ADS]) were
recorded from electronic prescribing records. The relationship and predictive ability of these were explored.
Results: The sample included 125 patients with DSM-IV diagnosed delirium and 122 patients without delirium. The
mean age of the sample was 84.0 years. The median number of drugs prescribed was 7: 79.8 % were prescribed ≥5
drugs and 29.0 % ≥10 drugs. The median ACB score was 1 and the median ADS score was 1.5. 73.4 % of patients had
an ACB score of ≥1 and 73.0 % had a ADS score ≥1. There was no association between: number of drugs prescribed,
rate of polypharmacy, rate of excessive polypharmacy, ACB score and ADS score, and a diagnosis of delirium on
admission. Only acetylcholinesterase inhibitor use predicted delirium (OR 3.86, p = 0.04) and the number of drugs
prescribed was negatively correlated with age (spearman rho = −0.18, p = 0.006).
Conclusion: Neither number of drugs prescribed, polypharmacy or anticholinergic burden were associated with
delirium on admission, questioning the clinical usefulness of anticholinergic drug scales. Further research is needed to
unpick fully the relationship between, drugs, anticholinergic burden, age, and prevalent delirium in older patients and
whether there is any role for these scales in clinical practice.
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Background
Delirium is an acute neuropsychiatric condition charac-
terised by deficits in attention and cognition [1]. Delirium
is important because it is common among older people
acutely admitted to hospital and is associated with greater
mortality, in-hospital falls and new institutionalization [2].
The aetiology of delirium is often multifactorial, however
studies have found drugs often account for a significant
proportion [3, 4]. Polypharmacy has been indicated as
a precipitating factor in the development of delirium
[5–7], as has the addition of multiple drugs as an in-
patient [8]. Furthermore, the use of specific medica-
tions or medication classes have been identified as
risk factors for the development of delirium [9]. Psycho-
tropic drugs, particularly those with anticholinergic prop-
erties, have been implicated as precipitants [10].
Further investigation into the role of anticholinergic
drugs in delirium is important as they are commonly
prescribed medications [11], and they are biologically
plausible as an aetiological factor in delirium [12].
Reduced cerebral acetylcholine has been hypothesized to
be the common final pathway in the development of
delirium in response to inflammation [13]. Delirium is
associated with an increased risk of incident cognitive
impairment [14] similar to that seen in chronic use of
anticholinergic drugs [15]. This has led to the develop-
ment of two methods to measure anticholinergic burden.
First, anticholinergic burden can be estimated by meas-
uring serum anticholinergic activity (SAA) in vitro. Sec-
ond, expert-based anticholinergic drug scales estimate
anticholinergic burden by assigning medications a score,
based on high- low risk, which are then combined to
produce an overall score for a patient. However, evi-
dence of association between SAA and anticholinergic
drug scales with delirium is contradictory [16–18]. Anti-
cholinergic drug burden on admission has been associ-
ated with an admission with delirium [19] and incident
delirium in patients admitted with acute stroke [20]. A
rise in anticholinergic drug burden as an inpatient has
also been associated with development of incident delir-
ium in palliative patients [21]. However, other studies
have found no association between the administration of
anticholinergic medications and the development of in-
cident delirium in older patients [22, 23], cancer patients
[24] and intensive care patients [25].
Delirium is associated with poor outcomes and a high
mortality rate [26] and early identification is important.
Identifying patients at risk of delirium early may help
improve detection and hence care, but it is not clear if
medication identification has a role in this. Further
research is needed to clarify which factors or scales
are clinically useful in predicting delirium. Therefore,
the aim of this study was to determine if anticholin-
ergic drug burden, as measured by simple scales, or
polypharmacy, were associated with delirium on ad-
mission to hospital.
Method
The objectives of this study were first to investigate
associations between anticholinergic burden, measured
through two different drug scales, and the presence of
delirium in older people presenting to an acute hospital
admission unit. Second, to investigate associations
between the number of drugs prescribed pre-admission
and the presence of polypharmacy with prevalent delir-
ium in older people presenting to an acute hospital
admission unit.
Study sample
Patients aged 70 years and over, with an unplanned
medical admission to a United Kingdom university
hospital between March 2013 and November 2014, were
screened for delirium. A diagnosis of delirium that met
the Diagnostic and Statistical Manual of Mental Disorders
(4th ed., text rev.; DSM-IV-TR; American Psychiatric
Association, 2000) criteria was then made. This utilized
screening with the Confusion Assessment Method (CAM)
[27], Abbreviated Mental Test Score (AMTS) [28], the
Digit Span test, and a detailed review of the medical notes.
An expert geriatrician (TAJ) completed all screening.
Potential participants who were unable to communicate
because of severe sensory impairment or inability to speak
in English were excluded, as were those deemed to be at
risk of imminent death.
Participants with delirium were recruited as part of a
larger study examining undiagnosed cognitive impair-
ment in people with delirium [29]. Routinely collected
data on a matched number of people screened as not
having delirium were also collected. These were age,
gender and hospital length of stay.
Drug data collection
Electronic prescribing records were used to collect
admission medications and drug reconciliation is
completed by pharmacists on the admissions ward to en-
sure accuracy of admission drug history. Drugs prescribed
within 48 h of admission were recorded as pre-admission
drugs. Clinical judgement was used to exclude drugs that
were likely to be an acute prescription on that admission;
by considering the likely indication, route of adminis-
tration and whether drugs were prescribed on dis-
charge. Both regular and PRN medications were included.
Vitamins, topical preparations and optic preparations
were included. Nutritional supplements were excluded.
Any herbal, complimentary and alternative medicines, or
over the counter medications regularly taken by the
patient were only included if they were prescribed on
admission to hospital. Polypharmacy was defined as
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5 or more drugs and excessive polypharmacy as 10 or
more drugs. The Anticholinergic Cognitive Burden Scale
(ACB) and the Anticholinergic Drug Scale (ADS) was then
calculated for each participant based on the recorded pre-
admission drugs. The ACB and ADS scores were chosen
as they are the most widely available scales. The DBI scale
is another available scale, this was not used as it is a less
specific measure of anticholinergic activity as it includes
all psychotropic drugs.
Statistical analysis
Data were analysed using IBM SPSS Statistics for Windows
(Version 22.0. Armonk, NY: IBM Corp.). Normality of data
was assessed using the Shapiro-Wilk test. Differences in
demographics, length of stay, number of drugs, polyphar-
macy, excessive polypharmacy and ACB and ADS scores be-
tween the delirium and no-delirium groups was assessed
using an unpaired T-test, the independent samples Mann–
Whitney U test, or Chi Squared test as appropriate.
Spearman Rank Coefficient was used to assess correlations
between continuous variables. Logistic regression was used
to generate odds ratios and 95 % confidence intervals with:
number of drugs, ACB score, ADS score, anticholinesterase
inhibitor use, and polypharmacy, as predictor variables
controlling for age as a recognized predictor of delirium.
The significance level was set at <0.05.
Results
Of 1327 patients screened for delirium 228 were diag-
nosed with delirium. Of the patients without delirium
data were collected for 125 patients to form the no-
delirium group. Of the 228 diagnosed with delirium 125
were recruited and they formed the delirium group. Four
patients from the no-delirium group were excluded as
they were already included in the delirium group during
a previous admission, giving a total sample of 251 (flow
chart available as Additional file 1). The mean age of the
sample was 84.0 (SD ±6.60) years. There was no signifi-
cant difference in age or gender between the two
groups. The median length of stay was 10 days (IQR
3–20). Participants in the delirium group stayed in
hospital significantly longer than patients in the no-
delirium group (15 vs 6 days respectively, p < 0.001).
The median number of drugs prescribed was 7 (IQR
5–10). Polypharmacy was present in 79.8 % of the sam-
ple and excessive polypharmacy was present in 29.0 %.
There was no difference between those with and without
delirium in number of drugs prescribed, or proportion
of those with polypharmacy.
The median ADS score was 1.5 (IQR 0–3) and the me-
dian ACB was 1 (IQR 0–2). The median ACB score was
the same in the delirium and no-delirium group. The
median ADS score was slightly higher in the no-delirium
group, 2, than in the delirium group, 1, but this was not
significant (p = 0.09) (Table 1).
The number of prescribed drugs was negatively corre-
lated with age (spearman rho = −0.176, p = 0.006). Acet-
lycholinesterase inhibitor prescription predicted delirium
on admission when controlling for age (OR 3.86, 95 %
CI 1.05–14.22, p = 0.04). Age, number of drugs, presence
of polypharmacy or excessive polypharmacy, ADS and
ACB scores did not predict delirium on admission.
Discussion
This observational case control study has demonstrated
no relationship between anticholinergic burden and
polypharmacy, with delirium in older people admitted to
an acute hospital. Increasing age is actually associated
with reduced number of drugs taken, and only taking
anticholinesterase inhibitor drugs are associated with
delirium. As expected the majority of older patients in
this study were taking a large number of medications,
Table 1 Comparing Demographics, Anticholinergic Burden and Polypharmacy between Delirium and No-delirium Groups
Study Population (n = 251) Delirium (n = 125) No-delirium (n = 122) Significance
Mean Age (years, SD) 83.97 (±6.60) 84.4 (±6.52) 83.54 (±6.67) p = 0.21
Female (%) 67.3 62.4 72.4 p = 0.95
Median Length of Stay (days, IQR) 10 (3–20) 15 (6–29) 6 (2–13) p < 0.001
Median drugs prescribed 7.00 (5–10) 7.00 (5–10) 7.00 (5–10) p = 0.72
Polypharmacy (%) 79.8 79.2 80.5 p = 0.80
Excessive Polypharmacy (%) 29.0 28.8 29.3 p = 0.94
Median ACB score 1.00 (0–2) 1.00 (0–3) 1.00 (1–2) P = 0.58
ACB score ≥1 (%) 73.4 68.8 78.0 p = 0.10
Median ADS score 1.50 (0–3) 1.00 (0–2.5) 2.00 (1–3) p = 0.09
ADS score ≥1 (%) 73.0 67.2 78.9 p = 0.39
AChE Inhibitor prescribed (%) 5.6 8.8 2.4 p = 0.030
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median 7 drugs, and 73 % were exposed to at least one
medication with anticholinergic effects. We found no re-
lationship between either of the anticholinergic drug
scales used in this study, ACB and ADS, and prevalent
delirium on admission to hospital. We also found no as-
sociation between the number of drugs patients were
prescribed, or the presence of polypharmacy and preva-
lent delirium. Use of Acetylcholinesterase inhibitors was
associated with delirium. Delirium is more common in
patients with dementia [3] and this likely explains the
correlation. However, acetylcholinesterase use is a poor
proxy measure for dementia. Polypharmacy was nega-
tively correlated with age in this population.
Strengths of the study include robust screening for de-
lirium by an expert against recognized criteria, and the
use of electronic records to accurately record admission
drugs. Recognized limitations are that the drug history
was taken in the acute setting which have been shown to
be unreliable [30], but the drug reconciliation by ward
based pharmacists, and the retrospective collection of
the drug history from the electronic record, should have
limited this potential bias. We did also recognize that
drug prescription is not a reliable indicator of patient
compliance. A further limitation is that due to study de-
sign we were not able to compare frailty or co-morbidity
between those with and without delirium. Given the con-
venience nature of the no-delirium group it was not pos-
sible to be confident about how representative this group
was of all patients without delirium.
This study supports previous work which has shown
no association between anticholinergic burden and de-
lirium [22–25]. However other studies have reported an
association [19, 20]. Studies have investigated different
patient populations and this may in part explain the
contrasting results. However, studies with a similar
population to this study, older patients admitted to
hospital, have also had mixed results [19, 22, 23]. The
populations investigated were similar with regards to
age. However, the cohort in the current study demon-
strates a higher burden of polypharmacy, suggesting the
cohort may be frailer and more multi-morbid, and per-
haps of greater representation of real world practice.
Contrasting results may also be explained by limita-
tions to the drug scales themselves. First, a number
of drugs scales have been developed and there are
variations between them. The ACB and ADS scales
were used in this study. The only study to investigate
a similar patient population and find positive results
was by Best et al. [19] and used the Drug Burden
Index (DBI) [31]. DBI is currently the only scale to
consider drug dose but is also a broader drug scale
including other sedative drugs without anticholinergic
effects [31]. These differences may explain the con-
trast in the results.
Second, use of anticholinergic medications is likely to
vary between populations and this may be reflected in
the development of anticholinergic drug scales [32]. The
use of scales in different populations may, therefore, not
accurately assess anticholinergic burden. Furthermore,
drug scales need to be regularly updated to include any
new medications with anticholinergic effects [32]. Third,
drug scales have been broadly criticised for oversimplify-
ing a complicated pharmacological issue. For example,
all scales use a simple linear additive model, however the
risk of anticholinergic effects may not increase in this
manner [33]. Also drug scales do not consider under-
lying patient characteristics including differences in
pharmacodynamics, cholinergic reserve and endogenous
anticholinergic activity [33]. These characteristics are
likely to be even more important in a population of
older patients, as investigated in this study.
This study shows a negative correlation between
age and the number of drugs prescribed, which is in
keeping with a previous report [34]. This may be
explained by first, that the oldest old (age ≥85) may
be healthier than those who die earlier, and therefore
take less medications; a survivor effect. Second, this
may be due to deprescribing in the oldest old as
medications are deemed clinically unnecessary to-
wards the end of life.
This study raises doubts about the clinical utility of
polypharmacy and anticholinergic drug scales, at pre-
dicting delirium in older hospital populations. However,
further research is needed to clarify this and to investi-
gate other factors, such as frailty, that may predispose
some older people with polypharmacy and high anti-
cholinergic drug use to delirium. Further research
could also investigate which specific anticholinergic
drug scale is most useful in delirium or the develop-
ment of new scales with fewer limitations. The relation-
ship between delirium, anticholinergic drug scale scores
and acetylcholine levels or serum anticholinergic levels
in vitro could also be investigated further. This may be
particularly important in older people who are more
likely to have decreased cholinergic reserve and more
variable pharmacodynamics.
Conclusion
Neither number of drugs prescribed, polypharmacy nor
anticholinergic burden were associated with delirium on
admission. This study contributes to an existing volume
of research which questions the usefulness of anticholin-
ergic drug scales in predicting delirium. Further research
is needed to fully unpick the relationship between drugs,
anticholinergic burden and prevalent delirium in older
patients, with a focus on additional factors which con-
tribute to patient vulnerability to delirium and its com-
plex aetiology.
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Additional file
Additional file 1: Figure S1. Flowchart of selection of study
participants. Flowchart demonstrating selection of participants to the
delirium and no-delirium groups and the number of patients recruited.
The number of patients excluded and not recruited are also displayed
and the reason they were not included. (DOCX 30 kb)
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